Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus + R-DHAP in Relapsed/Refractory DLBCL
NCT01653067Phase 2Unknown
- Start
- Sep 2012
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in diffuse large B-cell lymphoma (DLBCL). Primary endpoints: Maximum Tolerated Dose and Overall Response Rate. Status: unknown.
02
Drugs
temsirolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01653067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01653067.